These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18054795)

  • 1. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.
    Steensma DP; Heptinstall KV; Johnson VM; Novotny PJ; Sloan JA; Camoriano JK; Niblack J; Bennett JM; Mesa RA
    Leuk Res; 2008 May; 32(5):691-8. PubMed ID: 18054795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc.
    Heptinstall K;
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):13-8; discussion 19. PubMed ID: 18434977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.
    Clavio M; Nobili F; Balleari E; Girtler N; Ballerini F; Vitali P; Rosati P; Venturino C; Varaldo R; Gobbi M; Ghio R; Rodriguez G
    Eur J Haematol; 2004 Feb; 72(2):113-20. PubMed ID: 14962248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
    Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
    Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
    Nilsson-Ehle H; Birgegård G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engström LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellström-Lindberg E
    Eur J Haematol; 2011 Sep; 87(3):244-52. PubMed ID: 21623919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of quality of life for patients living with myelodysplastic syndromes.
    Thomas ML; Crisp N; Campbell K
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():47-57. PubMed ID: 22641284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.
    Cella D
    Semin Hematol; 1997 Jul; 34(3 Suppl 2):13-9. PubMed ID: 9253779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
    Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
    Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
    Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
    Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue.
    Caocci G; Baccoli R; Ledda A; Littera R; La Nasa G
    Leuk Res; 2007 Feb; 31(2):249-52. PubMed ID: 16814382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Meyers CA; Albitar M; Estey E
    Cancer; 2005 Aug; 104(4):788-93. PubMed ID: 15973668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
    Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
    Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.
    Jansen AJ; Essink-Bot ML; Beckers EA; Hop WC; Schipperus MR; Van Rhenen DJ
    Br J Haematol; 2003 Apr; 121(2):270-4. PubMed ID: 12694248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
    Efficace F; Gaidano G; Breccia M; Criscuolo M; Cottone F; Caocci G; Bowen D; Lübbert M; Angelucci E; Stauder R; Selleslag D; Platzbecker U; Sanpaolo G; Jonasova A; Buccisano F; Specchia G; Palumbo GA; Niscola P; Wan C; Zhang H; Fenu S; Klimek V; Beyne-Rauzy O; Nguyen K; Mandelli F
    Br J Haematol; 2015 Feb; 168(3):361-70. PubMed ID: 25272332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of myelodysplastic syndromes on quality of life: lessons learned from 70 voices.
    Thomas ML
    J Support Oncol; 2012; 10(1):37-44. PubMed ID: 22244675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes.
    Thomas ML
    Leuk Res; 1998 May; 22 Suppl 1():S41-7. PubMed ID: 9734699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.